SK1742003A3 - Therapeutic combinations of a CETP inhibitor and atorvastatin - Google Patents
Therapeutic combinations of a CETP inhibitor and atorvastatin Download PDFInfo
- Publication number
- SK1742003A3 SK1742003A3 SK174-2003A SK1742003A SK1742003A3 SK 1742003 A3 SK1742003 A3 SK 1742003A3 SK 1742003 A SK1742003 A SK 1742003A SK 1742003 A3 SK1742003 A3 SK 1742003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- pharmaceutically acceptable
- compound
- hydroxy
- ethyl
- trifluoromethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22523800P | 2000-08-15 | 2000-08-15 | |
| PCT/IB2001/001309 WO2002013797A2 (en) | 2000-08-15 | 2001-07-23 | Therapeutic combination of a cetp inhibitor and atorvastatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK1742003A3 true SK1742003A3 (en) | 2004-06-08 |
Family
ID=22844100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK174-2003A SK1742003A3 (en) | 2000-08-15 | 2001-07-23 | Therapeutic combinations of a CETP inhibitor and atorvastatin |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20020035125A1 (es) |
| EP (1) | EP1309329A2 (es) |
| JP (1) | JP2004506008A (es) |
| KR (1) | KR20030069983A (es) |
| CN (1) | CN1735416A (es) |
| AP (1) | AP2003002743A0 (es) |
| AU (1) | AU2001270937A1 (es) |
| BG (1) | BG107515A (es) |
| BR (1) | BR0113200A (es) |
| CA (1) | CA2419406A1 (es) |
| CZ (1) | CZ2003390A3 (es) |
| DZ (1) | DZ3409A1 (es) |
| EA (1) | EA200300155A1 (es) |
| EC (1) | ECSP034478A (es) |
| HR (1) | HRP20030104A2 (es) |
| HU (1) | HUP0303083A3 (es) |
| IL (1) | IL154348A0 (es) |
| IS (1) | IS6700A (es) |
| MX (1) | MXPA03001419A (es) |
| NO (1) | NO20030725D0 (es) |
| PA (1) | PA8525301A1 (es) |
| PE (1) | PE20020340A1 (es) |
| SK (1) | SK1742003A3 (es) |
| SV (1) | SV2003000600A (es) |
| TN (1) | TNSN01125A1 (es) |
| UY (1) | UY26883A1 (es) |
| WO (1) | WO2002013797A2 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044459A1 (en) * | 2001-09-04 | 2003-03-06 | Pfizer Inc. | Biomodulated multiparticulate formulations |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| JP2006512359A (ja) * | 2002-12-20 | 2006-04-13 | ファイザー・プロダクツ・インク | ＣＥＴＰ阻害薬及びＨＭＧ−ＣｏＡ還元酵素阻害薬を含有する剤形 |
| AU2003283769A1 (en) * | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| WO2004106299A2 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
| WO2005011634A1 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| WO2005030185A2 (en) | 2003-09-26 | 2005-04-07 | Japan Tobacco Inc. | Method of inhibiting remnant lipoprotein production |
| AU2005233160B2 (en) * | 2004-04-13 | 2011-06-02 | Merck Sharp & Dohme Corp. | CETP inhibitors |
| EP1845953A1 (en) * | 2005-02-03 | 2007-10-24 | Pfizer Products Incorporated | Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| EP3187182B1 (en) | 2008-09-02 | 2021-03-03 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| BRPI1007518A2 (pt) | 2009-02-10 | 2018-02-20 | Amarin Pharma, Inc. | uso de acido etil ester eicopentanoico para tratamento de hipertrigliceridemia |
| BRPI1011876B1 (pt) | 2009-04-29 | 2020-03-31 | Amarin Pharma, Inc. | Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular |
| EP2424521A4 (en) | 2009-04-29 | 2015-03-04 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE |
| DK2443246T3 (en) * | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ie Ltd | COMPOSITIONS AND METHODS FOR REDUCING TRIGLYCERIDES WITHOUT INCREASING LDL-C LEVELS IN AN INDIVIDUAL WITH CURRENT STATE THERAPY |
| RU2012116079A (ru) | 2009-09-23 | 2013-10-27 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения |
| NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
| EP4342546A3 (en) | 2012-06-29 | 2024-05-22 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6462091B1 (en) * | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
-
2001
- 2001-07-23 SK SK174-2003A patent/SK1742003A3/sk not_active Application Discontinuation
- 2001-07-23 KR KR10-2003-7002220A patent/KR20030069983A/ko not_active Application Discontinuation
- 2001-07-23 WO PCT/IB2001/001309 patent/WO2002013797A2/en not_active Application Discontinuation
- 2001-07-23 HU HU0303083A patent/HUP0303083A3/hu unknown
- 2001-07-23 EA EA200300155A patent/EA200300155A1/ru unknown
- 2001-07-23 AP APAP/P/2003/002743A patent/AP2003002743A0/en unknown
- 2001-07-23 CN CNA018150667A patent/CN1735416A/zh active Pending
- 2001-07-23 EP EP01949825A patent/EP1309329A2/en not_active Ceased
- 2001-07-23 CA CA002419406A patent/CA2419406A1/en not_active Abandoned
- 2001-07-23 JP JP2002518943A patent/JP2004506008A/ja not_active Withdrawn
- 2001-07-23 BR BR0113200-8A patent/BR0113200A/pt not_active IP Right Cessation
- 2001-07-23 IL IL15434801A patent/IL154348A0/xx unknown
- 2001-07-23 MX MXPA03001419A patent/MXPA03001419A/es not_active Application Discontinuation
- 2001-07-23 DZ DZ013409A patent/DZ3409A1/fr active
- 2001-07-23 AU AU2001270937A patent/AU2001270937A1/en not_active Abandoned
- 2001-07-23 CZ CZ2003390A patent/CZ2003390A3/cs unknown
- 2001-08-14 PE PE2001000810A patent/PE20020340A1/es not_active Application Discontinuation
- 2001-08-14 TN TNTNSN01125A patent/TNSN01125A1/fr unknown
- 2001-08-14 UY UY26883A patent/UY26883A1/es not_active Application Discontinuation
- 2001-08-14 PA PA20018525301A patent/PA8525301A1/es unknown
- 2001-08-14 US US09/929,862 patent/US20020035125A1/en not_active Abandoned
- 2001-08-14 SV SV2001000600A patent/SV2003000600A/es not_active Application Discontinuation
-
2003
- 2003-01-27 IS IS6700A patent/IS6700A/is unknown
- 2003-02-03 BG BG107515A patent/BG107515A/xx unknown
- 2003-02-13 HR HR20030104A patent/HRP20030104A2/hr not_active Application Discontinuation
- 2003-02-13 EC EC2003004478A patent/ECSP034478A/es unknown
- 2003-02-14 NO NO20030725A patent/NO20030725D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IS6700A (is) | 2003-01-27 |
| KR20030069983A (ko) | 2003-08-27 |
| TNSN01125A1 (fr) | 2005-11-10 |
| NO20030725D0 (no) | 2003-02-14 |
| AP2003002743A0 (en) | 2003-03-31 |
| US20020035125A1 (en) | 2002-03-21 |
| CN1735416A (zh) | 2006-02-15 |
| EA200300155A1 (ru) | 2003-08-28 |
| MXPA03001419A (es) | 2003-06-06 |
| UY26883A1 (es) | 2002-03-22 |
| HUP0303083A2 (hu) | 2003-12-29 |
| SV2003000600A (es) | 2003-01-13 |
| PA8525301A1 (es) | 2002-04-25 |
| CZ2003390A3 (en) | 2004-03-17 |
| WO2002013797A2 (en) | 2002-02-21 |
| IL154348A0 (en) | 2003-09-17 |
| WO2002013797A3 (en) | 2003-03-13 |
| BG107515A (en) | 2003-09-30 |
| BR0113200A (pt) | 2003-09-16 |
| JP2004506008A (ja) | 2004-02-26 |
| AU2001270937A1 (en) | 2002-02-25 |
| DZ3409A1 (fr) | 2002-02-21 |
| HUP0303083A3 (en) | 2005-05-30 |
| ECSP034478A (es) | 2003-03-31 |
| HRP20030104A2 (en) | 2003-04-30 |
| PE20020340A1 (es) | 2002-05-10 |
| CA2419406A1 (en) | 2002-02-21 |
| EP1309329A2 (en) | 2003-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK1742003A3 (en) | Therapeutic combinations of a CETP inhibitor and atorvastatin | |
| US6455574B1 (en) | Therapeutic combination | |
| US6262092B1 (en) | Mutual salt of amlodipine and atorvastatin | |
| US20020025981A1 (en) | Combination therapy | |
| US20070149578A1 (en) | Combination Therapy | |
| EP1180102B1 (en) | Mutual prodrugs of amlodipine and atorvastatin | |
| OA12363A (en) | Therapeutic combination of a CETP inhibitor and atTartrate salts of thiazolidinedione derivative. orvastatin. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |